1-4 of 4
antibody-dependent cell cytotoxicity
Close
Sort by
Journal Articles

The selection of variable regions affects effector mechanisms of IgA antibodies against CD20

Mitchell Evers, Thies Rösner, Anna Dünkel, J. H. Marco Jansen, Niklas Baumann, Toine ten Broeke, Maaike Nederend, Klara Eichholz, Katja Klausz, Karli Reiding, Denis M. Schewe, Christian Kellner, Matthias Peipp, Jeanette H. W. Leusen, Thomas Valerius
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3807–3820.
https://doi.org/10.1182/bloodadvances.2021004598
Published: 2021
Includes: Supplemental data
Journal Articles

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Hilma J. van der Horst, Anne T. Gelderloos, Martine E. D. Chamuleau, Esther C. W. Breij, Sonja Zweegman, Inger S. Nijhof, Marije B. Overdijk, Tuna Mutis
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2165–2172.
https://doi.org/10.1182/bloodadvances.2020003731
Published: 2021
Includes: Supplemental data
Journal Articles

Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

Emily M. McWilliams, Christopher R. Lucas, Timothy Chen, Bonnie K. Harrington, Ronni Wasmuth, Amanda Campbell, Kerry A. Rogers, Carolyn M. Cheney, Xiaokui Mo, Leslie A. Andritsos, Farrukh T. Awan, Jennifer Woyach, William E. Carson, III, Jonathan Butchar, Susheela Tridandapani, Erin Hertlein, Carlos E. Castro, Natarajan Muthusamy, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (3): 447–460.
https://doi.org/10.1182/bloodadvances.2018025684
Published: 2019
Includes: Supplemental data
Journal Articles

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W. C. J. van de Donk, Pamela L. Clemens, A. Kate Sasser
Journal: Blood Advances
Blood Adv (2017) 1 (23): 2105–2114.
https://doi.org/10.1182/bloodadvances.2017006866
Published: 2017
Includes: Supplemental data